Key findings
- During this reporting period (10 October 2022 to 2 July 2023), 2876 people across Australia participated in the TraX study. Most participants were from New South Wales (83.9%).
- Throughout the study, monthly rates of testing for mpox remained consistent at approximately 1.0%. However, these rates have further reduced to 0.5% in the more recent reporting period.
- At study entry, 22.2% of participants reported being unvaccinated against mpox, 50.2% had received one vaccination, and 27.6% had received two mpox vaccinations.
- As of 2 July 2023, the proportion of people who reported being unvaccinated against mpox had reduced by more than half to 9.4%, leaving 271 participants unvaccinated. The proportion who reported having received only one mpox vaccination also fell to 11.1% and the proportion who had received both mpox vaccinations increased to 79.5%.
- At study entry, 12 participants reported prior mpox infection. No new mpox infections were reported throughout the study period.
